State Street’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

State Street’s Portfolio VYNT Stock Details VYNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15,038	Closed	-$8.72K	–	4807
2023 Q1	$8.72K	Hold	15,038	–	–	﹤0.01%	4751
2022 Q4	$10.6K	Sell	15,038 -2	-0%	-$3	﹤0.01%	4800
2022 Q3	$42K	Hold	15,040	–	–	﹤0.01%	4694
2022 Q2	$68K	Buy	15,040 +640	+4%	+$2.81K	﹤0.01%	4658
2022 Q1	$103K	Buy	14,400 +1,266	+10%	+$7.36K	﹤0.01%	4634
2021 Q4	$89K	Hold	13,134	–	–	﹤0.01%	4604
2021 Q3	$153K	Buy	13,134 +2,580	+24%	+$35.7K	﹤0.01%	4445
2021 Q2	$197K	Buy	+10,554	New	+$197K	﹤0.01%	4216

Other funds holding VYNT

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

State Street's VYNT Position: Q2 2023 in Review

State Street sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q2 2023, closing a stake of 15,038 shares — an estimated $8.72K sold.

State Street first reported a position in VYNT in Q2 2021 and held it in 8 quarters. The position peaked at $197K in Q2 2021. 1 fund tracked by Wall St. Rank holds VYNT as of Q2 2023.

State Street reported no remaining Vyant Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
State Street sold 15,038 Vyant Bio, Inc. Common Stock shares in Q2 2023, an estimated $8.72K.
State Street first reported a position in Vyant Bio, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
State Street's Vyant Bio, Inc. Common Stock position peaked at $197K in Q2 2021.
1 fund tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q2 2023.

Based on State Street's 13F filing for Q2 2023, filed 14 Aug 2023.